ESR1 and cancer: However, as shown in our results, many pathways in addition to the MEK pathway are also upregulated in ovarian, endometrial, and cervical cancers with high ER signaling activity (Fig. 5a), so targeting of more than two pathways may be needed for cancer cell proliferation inhibition.